Q&A: A decade on, what’s next for CAR-T therapies?
Pharmaceutical Technology
APRIL 5, 2023
But access to these treatments continues to remain limited due to high price tags and variable availability across regions. And coming back to the ISCT, we have a series of roundtables that go beyond the traditional didactic sessions, which address the issue of patient access. We must approach this on several fronts.
59 
Let's personalize your content